Article
Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.
Journal of hepatology - 1 Dec 2024
Kundu Juthika, Le Hoa T, Logan Michael, Hockman Darren, Landi Abdolamir, Crawford Kevin, Wininger Mark, Johnson Janelle, Kundu Joydeb K, Tiffney E Alana, Urbanowicz Richard A, Ball Jonathan K, Bailey Justin R, Bukh Jens, Law Mansun, Foung Steven, Tyrrell D Lorne, Houghton Michael, Law John Lokman
Abstract excerpt
BACKGROUND & AIMS: An optimal HCV vaccine requires the induction of antibodies that neutralise the infectivity of many heterogenous viral isolates. In this study, we have focused on determining the optimal recombinant envelope glycoprotein component to elicit cross-neutralising antibodies against global HCV genotypes. We compared the immunoreactivity and antigenicity of the HCV genotype 1a strain H77C-derived...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
